Clinical Scorecard: Addressing Obesity: A Critical Focus for Cardiovascular Health
At a Glance
Category
Detail
Condition
Obesity as a chronic disease and a key driver of cardiovascular disease (CVD)
Key Mechanisms
Excess/dysfunctional adiposity causing metabolic and neurohormonal maladaptations leading to CVD onset and progression
Target Population
Individuals with overweight/obesity, especially those with established CVD or at high cardiovascular risk
Care Setting
Multidisciplinary healthcare settings including cardiovascular medicine and primary care
Key Highlights
Obesity is a progressive chronic disease and a powerful upstream driver of major CVD risk factors and several forms of CVD including atherosclerotic CVD, arrhythmia, and heart failure.
Recent randomized clinical trials (e.g., SELECT, FLOW) demonstrate that GLP-1 receptor agonists like semaglutide reduce cardiovascular events, improve metabolic and kidney outcomes, and aid weight loss.
Approach obesity as a chronic disease with diagnosis beyond BMI, incorporating individualized risk stratification.
Implement non-stigmatized behavioral and lifestyle counseling for all individuals irrespective of BMI.
Management
Prioritize multi-modality treatment including pharmacotherapies such as GLP-1 receptor agonists for individuals with overweight/obesity and CVD or high cardiovascular risk.
Maintain foundational health behaviors including physical activity and nutrition as core components of obesity management.
Adopt upstream promotive and preventive strategies targeting overweight/obesity to reduce population-level cardiovascular risk.
Monitoring & Follow-up
Regularly monitor cardiovascular risk factors, metabolic health, kidney function, and weight status in individuals with obesity.
Evaluate treatment response including weight loss, blood pressure, glycemic control, and cardiovascular outcomes.
Risks
Recognize obesity-associated risks beyond CVD including anemia, cancer, infection, osteoarthritis, pregnancy-related disorders, mental health disorders, respiratory disorders, and venous thromboembolism.
Be aware of the high cost and limited access to newer anti-obesity medications, prioritizing treatment for those at highest short-term absolute risk.
Patient & Prescribing Data
Individuals with overweight/obesity, including those with established cardiovascular disease and type 2 diabetes
GLP-1 receptor agonists such as semaglutide and tirzepatide have demonstrated significant benefits in reducing cardiovascular events, improving kidney outcomes, and alleviating heart failure symptoms in obesity-related conditions.
Clinical Best Practices
Expand clinician expertise in obesity pathophysiology and individualized treatment approaches beyond BMI.
Integrate obesity management as a core component of comprehensive cardiovascular risk reduction across the lifespan.
Implement non-stigmatizing lifestyle counseling universally to improve metabolic health and prevent obesity onset.
Utilize evidence-based pharmacotherapies targeting metabolic and neurohormonal mechanisms in addition to lifestyle interventions.
Promote upstream preventive strategies to address obesity before the development of costly and disabling complications.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
